Table 2.

 Genotype frequencies and log‐rank P values for VEGFA and VEGFR2 polymorphisms in patients with diffuse large B cell lymphoma

Gene	ID no.	Base change	Genotype		Log‐rank P for OS			Log‐rank P for PFS			MAF in healthy population
			MAF	HWE P	Additive	Dominant	Recessive	Additive	Dominant	Recessive	Korean	Asian	European†	African†
VEGFA	rs699947	−2578C>A	0.226	0.997	0.429	0.629	0.194	0.530	0.485	0.464	0.340‡	0.318	0.408	0.117
	rs2010963	+405G>C	0.337	0.687	0.882	0.991	0.650	0.812	0.940	0.562	0.519§	0.352	0.431	0.340
	rs3025039	+936C>T	0.154	0.055	0.497	0.543	0.437	0.289	0.348	0.318	0.206§	0.182	0.186	0.068
VEGFR2	rs1870377	+1416T>A	0.322	0.253	0.004	0.002	0.021	0.010	0.004	0.049	–	0.344	0.275	0.117
	rs2305948	+1192G/A	0.121	0.463	0.966	0.823	0.929	0.997	0.968	0.953	–	0.078	0.067	0.292

In the reference sequence, the transcription start site was designated nt +1. †Information about polymorphism ID and MAF in other ethnic populations (Asian, European and African‐American) were obtained from the National Center for Biotechnology Information database (http://www.ncbi.nlm.nih.gov). ‡From reference 43. §From reference 44. HWE, Hardy–Weinberg equilibrium; ID, identification; MAF, minor allele frequency; OS, overall survival; PFS, progression‐free survival; VEGFA, vascular endothelial growth factor A; VEGFR2, vascular endothelial growth factor receptor 2.